Holen Sie sich die Stockscreener-App
1.31
0.00%
0.00
Handel nachbörslich:
1.31
Schlusskurs vom Vortag:
$1.31
Offen:
$1.28
24-Stunden-Volumen:
2.02M
Relative Volume:
1.10
Marktkapitalisierung:
$497.57M
Einnahmen:
$106.34M
Nettoeinkommen (Verlust:
$-74.66M
KGV:
-1.3789
EPS:
-0.95
Netto-Cashflow:
$-46.12M
1W Leistung:
+2.34%
1M Leistung:
-0.76%
6M Leistung:
-1.50%
1J Leistung:
-19.63%
1-Tages-Spanne:
$1.22
$1.325
1-Wochen-Bereich:
$1.205
$1.33
52-Wochen-Spanne:
$0.92
$2.32
Standard Biotools Inc Stock (LAB) Company Profile
Firmenname
Standard Biotools Inc
Sektor
Branche
Telefon
(650) 266-6000
Adresse
2 TOWER PLACE, SOUTH SAN FRANCISCO
Vergleichen Sie LAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
1.31 | 473.23M | 106.34M | -74.66M | -46.12M | -0.95 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-27 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2024-04-16 | Eingeleitet | TD Cowen | Buy |
| 2024-04-04 | Eingeleitet | Jefferies | Buy |
| 2023-07-12 | Eingeleitet | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc Aktie (LAB) Neueste Nachrichten
TD Cowen Downgrades Standard BioTools to Hold From Buy, $1.60 Price Target - MarketScreener
Standard BioTools Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - uk.finance.yahoo.com
Can Traders Expect Breakout From Standard BioTools Inc. This Week [Sell Signal]Free Weekly Breakout Stock Alerts - 선데이타임즈
Standard BioTools stock holds Sector Weight rating at KeyBanc amid M&A potential - Investing.com Australia
KeyBanc Maintains Standard BioTools(LAB.US) With Hold Rating - 富途牛牛
Standard BioTools Delays Quarterly Report Filing - TipRanks
Standard BioTools Reports Q2 2025 Financial Results - TipRanks
Standard BioTools Reports Q2 Loss, Tops Revenue Estimates - AInvest
Standard BioTools Expects FY25 Revenue of $165M-$175M - AInvest
Standard BioTools Steadies Revenue Despite Tough Market Headwinds - Finimize
Standard BioTools (LAB) Reports Q2 Loss, Tops Revenue Estimates - Nasdaq
Standard BioTools: Q2 Earnings Snapshot - San Francisco Chronicle
Standard BioTools Q2 rev. $42mln, SomaLogic sold to Illumina for up to $425mln. - AInvest
Standard BioTools Announces SomaLogic Sale to Illumina - TipRanks
Standard Biotools earnings beat by $0.02, revenue fell short of estimates - Investing.com Canada
Standard BioTools Q2 revenue dips 3% - MarketScreener
Standard BioTools Reports Second Quarter 2025 Financial Results - The Manila Times
Standard BioTools' Five-Year Share Price Down 84%, Revenue Growth of 3.1% - AInvest
The past five years for Standard BioTools (NASDAQ:LAB) investors has not been profitable - Yahoo Finance
Standard BioTools LAB Q2 2025 Earnings Preview Upside Potential on Strategic Expansion - AInvest
Standard BioTools Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Standard BioTools Q2 2025 Earnings Preview - MSN
Standard BioTools Q2 2025 Earnings Outlook: Strategic Shifts, Revenue Pressures, and the Path to Value Creation - AInvest
What to Expect from Standard BioTools Inc (LAB) Q2 2025 Earnings - Yahoo Finance
Standard BioTools Partners with Precision Health in Singapore for Proteomic Collaboration - AInvest
Standard BioTools and Precision Health Research, Singapore - GlobeNewswire
Major Win: Standard BioTools Secures 100,000-Sample Singapore Biobank Deal for Population Health Study - Stock Titan
Why is Standard BioTools Inc. stock attracting strong analyst attentionUnlock daily stock market insights for success - Jammu Links News
How volatile is Standard BioTools Inc. stock compared to the marketInvest smarter with daily market updates - Jammu Links News
Is Standard BioTools Inc. a growth stock or a value stockBuild wealth with steady, reliable stocks - Jammu Links News
What analysts say about Standard BioTools Inc. stockInvest confidently with data-backed picks - Jammu Links News
How many analysts rate Standard BioTools Inc. as a “Buy”Maximize returns with effective portfolio management - Jammu Links News
What institutional investors are buying Standard BioTools Inc. stockDiscover stocks with explosive potential - Jammu Links News
What makes Standard BioTools Inc. stock price move sharplyMaximize your portfolio’s growth potential - Jammu Links News
Is Standard BioTools Inc. stock overvalued or undervaluedFree Popular Stock Recommendations - Jammu Links News
Is it the right time to buy Standard BioTools Inc. stockInvest smarter with expert stock recommendations - Jammu Links News
What catalysts could drive Standard BioTools Inc. stock higher in 2025Exceptional stock performance - Jammu Links News
What are Standard BioTools Inc. company’s key revenue driversUnlock hidden market opportunities today - Jammu Links News
What are the technical indicators suggesting about Standard BioTools Inc.Build wealth faster with consistent growth stocks - Jammu Links News
When is Standard BioTools Inc. stock expected to show significant growthUnlock expert insights for smarter investing - Jammu Links News
Standard BioTools Approves Stock Awards for Executives - The Globe and Mail
Standard BioTools Inc. Building a Base Near SupportConservative Entry for High Return Setup Backed - beatles.ru
Standard BioTools grants RSU awards to CEO and CFO, increases CFO bonus target - Investing.com Australia
Illumina Beats Q2 Earnings Expectations, Boosts 2025 Outlook Despite Revenue Dip - Stock Titan
Trend analysis for Standard BioTools Inc. this weekFast Return Equity Trade Forecast Points to Small Caps - metal.it
Standard BioTools Inc. At Critical Juncture — Bounce or BreakdownTrade Scanner With Buy Zone Alerts Flagged - metal.it
Best data tools to analyze Standard BioTools Inc. stockAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Finanzdaten der Standard Biotools Inc-Aktie (LAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):